Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disorder of the gastrointestinal (GI) tract that significantly impacts the quality of… read more.
New research from the University of Georgia suggests the COVID-19 pandemic may have had an unexpected side effect for postpartum women: more benzodiazepine prescriptions. The new study found that the pandemic… read more.
Summit Therapeutics Inc. announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented… read more.
Children with asthma who are exposed to high levels of indoor allergens, such as cockroach and mouse allergens, are at an increased risk of developing respiratory viral infections… read more.
A pharmacy professor at Binghamton University, State University of New York has a $1.9 million grant from the National Institute of General Medical Sciences to tackle gene therapy challengs…. read more.
Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, has announced the commercial launch of Gemtesa (vibegron) 75 mg tablets, a beta-3… read more.
The European Medicines Agency (EMA) has approved the pre-filled syringe for the administration of Eylea™ 8 mg (114.3 mg/ml solution for injection) in the European Union. The new… read more.
A new study reveals that young patients treated with psychiatric medications receive potentially dangerous combinations with concerning frequency. Researchers from Rutgers Health and other institutions analyzed New York… read more.
Gilead Sciences, Inc. announced that the FDA has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA)… read more.
Over-the-counter blood pressure measuring devices offer a simple, affordable way for people to track hypertension at home, but the standard arm-size ranges for these devices won’t appropriately fit… read more.
Avadel Pharmaceuticals plc , announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime Lumryz versus a twice-nightly immediate-release oxybate treatment… read more.
According to research presented at ESC Congress 2024,1 women with endometriosis have a 20% greater risk of significant cardiac outcomes compared with women without endometriosis. “For decades, cardiovascular… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
